TEL AVIV, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporfin vascular targeted photodynamic (VTP) therapy to treat a ...
- Complete response (CR) observed in 70% (35/50) of patients with low-grade upper tract urothelial cancer (UTUC) who completed the Induction Treatment Phase (ITP) - Initial durability data shows all ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback